Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES VOTING RESULTS FROM ITS ANNUAL GENERAL AND SPECIAL MEETING

Helix BioPharma Corp. has released the voting results from the annual general and special meeting of its shareholders held on Wednesday, March 26, 2025. A total of 40,294,667 common shares were voted at the meeting, representing 76.00 per cent of Helix's total issued and outstanding shares.

Shareholders voted overwhelmingly in favour of all items of business before the meeting. The four director nominees listed in Helix's management information circular dated Jan. 31, 2025, were re-elected as directors of the company to hold office for the ensuing year or until their successors are elected or appointed. The detailed results of the vote for each director are set out in the attached table.

The resolutions to appoint Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting at remuneration to be determined by the directors, were approved with 99.61 per cent of the votes cast in favour.

The resolution regarding the asset transactions contemplated by the asset purchase agreements with Laevoroc Immunology AG and Laevoroc Chemotherapy AG dated Nov. 28, 2024, and Nov. 30, 2024, respectively, each as amended on Dec. 5, 2024, in accordance with the policies of the Toronto Stock Exchange (TSX), was approved with 99.61 per cent of the votes cast in favour.

The resolution regarding the equity drawdown subscription facility that may provide the company with access to funds of up to $25-million, as contemplated in the term sheet dated Oct. 15, 2024, between the company and GEM Yield Bahamas Ltd. (GYBL) and the share subscription agreement to be entered into among the company, GYBL, GEM Global Yield LLC SCS and certain holders of unrestricted common shares following TSX and shareholder approval, was approved with 99.61 per cent of the votes cast in favour.

The resolution regarding the amendment to the articles of the company to effect a consolidation of the issued and outstanding common shares on the basis of a consolidation ratio selected by the board of directors of the company of up to five preconsolidation common shares for one postconsolidation common share, and to authorize the board to determine the final consolidation ratio at its sole discretion, as more particularly described in the information circular, was approved with 99.98 per cent of the votes cast in favour.

The resolution regarding the change of name of the company to Aconara Pharma Corp. or such other name as the board may determine was approved with 99.60 per cent of the votes cast in favour.

The resolution regarding, with or without variation, (i) the approval of all unallocated options, rights and other entitlements under Helix's equity compensation plan; and (ii) the confirmation and approval of such plan; and (iii) the approval of the granting by Helix of options, rights and other entitlements under such plan for a further three years, was approved with 99.60 per cent of the votes cast in favour.

A report on all items of business voted at the meeting will be filed on SEDAR+.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a near future where today's hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The company innovates from strength to tackle cancer's biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, Tumour Defence Breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today's front-running anti-cancer therapies. L-DOS47 has completed phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bispecific ADCs targeting CEACAM6 in discovery.

We seek Safe Harbor.